Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 Jan 29;9(1):e87671.
doi: 10.1371/journal.pone.0087671. eCollection 2014.

Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis

Yi Xiao  1 , Jin Yin  1 , Jia Wei  1 , Zhen Shang  1
Affiliations
Meta-Analysis

Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis

Yi Xiao et al. PLoS One. .

Abstract

Background: We conducted a systematic review and meta-analysis to clarify the incidence and risk of cardiotoxicity associated with bortezomib in cancer patients.

Methods: Databases from PubMed, Web of Science and abstracts presented at ASCO meeting up to July 31, 2013 were searched to identify relevant studies. Eligible studies included prospective phase II and III trials evaluating bortezomib in cancer patients with adequate data on cardiotoxicity. Statistical analyses were conducted to calculate the summary incidence, odds ratio (OR) and 95% confidence intervals (CIs) by using either random effects or fixed effect models according to the heterogeneity of included studies.

Results: A total of 5718 patients with a variety of malignancies from 25 clinical trials were included in our analysis. The incidence of all-grade and high-grade cardiotoxicity associated with bortezomib was 3.8% (95%CI: 2.6-5.6%) and 2.3% (1.6-3.5%), with a mortality of 3.0% (1.4-6.5%). Patients treated with bortezomib did not significantly increase the risk of all-grade (OR 1.15, 95%CI: 0.82-1.62, p=0.41) and high-grade (OR 1.13, 95%CI: 0.58-2.24, p=0.72) cardiotoxicity compared with patients treated with control medication. Sub-group analysis showed that the incidence of cardiotoxicity varied with tumor types, treatment regimens and phases of trials. No evidence of publication bias was observed.

Conclusions: The use of bortezomib does not significantly increase the risk of cardiotoxicity compared to control patients. Further studies are recommended to investigate this association and risk differences among different tumor types, treatment regimens and phases of trials.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Selection process for clinical trials included in the meta-analysis.
Figure 2
Figure 2. Incidence of all-grade cardiotoxicity associated with bortezomib.
Figure 3
Figure 3. Incidence of high-grade cardiotoxicity associated with bortezomib.
Figure 4
Figure 4. Odds ratio of all-grade and high-grade cardiotoxicity associated with bortezomib vs. control.
See this image and copyright information in PMC

References

    1. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, et al. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101: 2377–2380. - PubMed
    1. Lu G, Punj V, Chaudhary PM (2008) Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL. Cancer Biol Ther 7: 603–608. - PubMed
    1. Galimberti S, Canestraro M, Pacini S, Fazzi R, Orciuolo E, et al. (2008) PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells. Leuk Res 32: 103–112. - PubMed
    1. Baiz D, Pozzato G, Dapas B, Farra R, Scaggiante B, et al. (2009) Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Biochimie 91: 373–382. - PubMed
    1. Paramore A, Frantz S (2003) Bortezomib. Nat Rev Drug Discov 2: 611–612. - PubMed

Publication types